Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chrysophanol is a natural anthraquinone derivative found in several plants, most notably in the genus *Rheum* (rhubarb). It is a key bioactive constituent of the traditional Chinese medicine formula Shenkang injection (SKI). Research indicates that chrysophanol exerts renoprotective effects by inhibiting the activation of the renin-angiotensin system (RAS) and the Wnt/β-catenin signaling pathway. Specifically, it has been shown to reduce the expression of Wnt1 and β-catenin, thereby suppressing downstream targets like Snail1, Twist, and MMP-7, which are involved in epithelial-to-mesenchymal transition (EMT) and renal fibrosis. It is primarily investigated for its potential in treating chronic kidney disease and associated tubulointerstitial fibrosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chrysophanol.